These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
181 related items for PubMed ID: 15043759
1. A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]. Hogg RJ, Wyatt RJ, Scientific Planning Committee of the North American IgA Nephropathy Study. BMC Nephrol; 2004 Mar 25; 5():3. PubMed ID: 15043759 [Abstract] [Full Text] [Related]
2. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ. Am J Kidney Dis; 2015 Nov 25; 66(5):783-91. PubMed ID: 26209543 [Abstract] [Full Text] [Related]
3. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. Hou JH, Le WB, Chen N, Wang WM, Liu ZS, Liu D, Chen JH, Tian J, Fu P, Hu ZX, Zeng CH, Liang SS, Zhou ML, Zhang HT, Liu ZH. Am J Kidney Dis; 2017 Jun 25; 69(6):788-795. PubMed ID: 28215945 [Abstract] [Full Text] [Related]
4. Immunosuppressive agents for treating IgA nephropathy. Natale P, Palmer SC, Ruospo M, Saglimbene VM, Craig JC, Vecchio M, Samuels JA, Molony DA, Schena FP, Strippoli GF. Cochrane Database Syst Rev; 2020 Mar 12; 3(3):CD003965. PubMed ID: 32162319 [Abstract] [Full Text] [Related]
5. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G. Nephrol Dial Transplant; 2005 Oct 12; 20(10):2139-45. PubMed ID: 16030050 [Abstract] [Full Text] [Related]
6. Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children. Kang Z, Li Z, Duan C, Wu T, Xun M, Ding Y, Zhang Y, Zhang L, Yin Y. Pediatr Nephrol; 2015 Jul 12; 30(7):1121-9. PubMed ID: 25773534 [Abstract] [Full Text] [Related]
7. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF. Kidney Int; 2004 May 12; 65(5):1842-9. PubMed ID: 15086925 [Abstract] [Full Text] [Related]
8. Immunosuppressive agents for treating IgA nephropathy. Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, Molony DA, Schena FP, Strippoli GF. Cochrane Database Syst Rev; 2015 Aug 03; (8):CD003965. PubMed ID: 26235292 [Abstract] [Full Text] [Related]
9. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial. Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, Nie S, Liang M, Wang G, Jia N, MAIN Trial Investigators. JAMA Netw Open; 2023 Feb 01; 6(2):e2254054. PubMed ID: 36745456 [Abstract] [Full Text] [Related]
10. Mycophenolate Mofetil: A Possible Alternative Treatment for IgA Nephropathy. Baraldi O, Comai G, Cuna V, Cappuccilli M, Serra C, Ronco C, La Manna G. Contrib Nephrol; 2017 Feb 01; 190():108-116. PubMed ID: 28535523 [Abstract] [Full Text] [Related]
11. Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis. Xu G, Tu W, Jiang D, Xu C. Am J Nephrol; 2009 Feb 01; 29(5):362-7. PubMed ID: 18974636 [Abstract] [Full Text] [Related]
12. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. Dal Canton A, Amore A, Barbano G, Coppo R, Emma F, Grandaliano G, Klersy C, Perfumo F, Rizzoni G, Schena FP, Sepe V, Angiotensin Inhibition Mycophenolate mophetil IgA Nephropathy study investigators. J Nephrol; 2005 Feb 01; 18(2):136-40. PubMed ID: 15944996 [Abstract] [Full Text] [Related]
13. Treatment of Patients with IgA Nephropathy: Evaluation of the Safety and Efficacy of Mycophenolate Mofetil. Chen Z, Chen W, Zheng L, Xie Y, Yao K, Zhou T. Curr Pharm Des; 2024 Feb 01; 30(30):2400-2409. PubMed ID: 38988169 [Abstract] [Full Text] [Related]
14. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: A network meta-analysis. Liu T, Wang Y, Mao H, Yang L, Zhan Y. Medicine (Baltimore); 2021 Feb 26; 100(8):e24541. PubMed ID: 33663060 [Abstract] [Full Text] [Related]
15. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW, Lai KN. Kidney Int; 2005 Aug 26; 68(2):802-12. PubMed ID: 16014059 [Abstract] [Full Text] [Related]
16. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN. Kidney Int; 2010 Mar 26; 77(6):543-9. PubMed ID: 20032964 [Abstract] [Full Text] [Related]
17. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S. Nephrol Dial Transplant; 2009 Jan 26; 24(1):156-60. PubMed ID: 18685141 [Abstract] [Full Text] [Related]
18. Treatment of IgA nephropathy: corticosteroids, tonsillectomy, and mycophenolate mofetil. Kawamura T. Contrib Nephrol; 2007 Jan 26; 157():37-43. PubMed ID: 17495435 [Abstract] [Full Text] [Related]
19. Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review. Tan CH, Loh PT, Yang WS, Chan CM. Singapore Med J; 2008 Oct 26; 49(10):780-5. PubMed ID: 18946610 [Abstract] [Full Text] [Related]
20. Treatment and outcome of IgA nephropathy in children from one single center experience. Mao Y, Zhou W, Zhou Z, Zhang C, Shen J, Yin L. BMC Pediatr; 2023 Jul 26; 23(1):377. PubMed ID: 37495962 [Abstract] [Full Text] [Related] Page: [Next] [New Search]